Efficacy of teriparatide and denosumab combination treatment in a patient with atypical femoral fracture and Behçet’s disease: a case report and review of the literature

References

• Jang SP, Yeo I, So SY, et al. Atypical femoral shaft fractures in female bisphosphonate users were associated with an increased anterolateral femoral bow and a thicker lateral cortex: a case-control study. Biomed Res Int. 2017;2017:5932496.
   Google Scholar
• Diab DL, Watts NB. Denosumab in osteoporosis. Expert Opin Drug Saf. 2014;13:247–253.
   PubMed Web of Science ®Google Scholar
• Thompson RN, Armstrong CL, Heyburn G. Bilateral atypical femoral fractures in a patient prescribed denosumab: a case report. Bone. 2014;61:44–47.
   PubMed Web of Science ®Google Scholar
• Chiang CY, Zebaze RM, Ghasem-Zadeh A, et al. Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy. Bone. 2013;52:360–365.
   PubMed Web of Science ®Google Scholar
• Miyakoshi N, Aizawa T, Sasaki S, et al. Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: a comparison between treatment with and without teriparatide. J Bone Miner Metab. 2015;33:553–559.
   PubMed Web of Science ®Google Scholar
• Saleh A, Hegde VV, Potty AG, et al. Management strategy for symptomatic bisphosphonate-associated incomplete atypical femoral fractures. HSS J. 2012;8:103–110.
   PubMedGoogle Scholar
• Tsai JN, Uihlein AV, Lee H, et al. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial. Lancet. 2013;382:50–56.
   PubMed Web of Science ®Google Scholar
• Schilcher J, Michaëlsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011;364:1728–1737.
   PubMed Web of Science ®Google Scholar
• Papapoulos S, Lippuner K, Roux C, et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporos Int. 2015;26:2773–2783.
   PubMed Web of Science ®Google Scholar
• Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29:1–23.
   PubMed Web of Science ®Google Scholar
• Alonso N, Soares DC, V McCloskey E, et al. Atypical femoral fracture in osteoporosis pseudoglioma syndrome associated with two novel compound heterozygous mutations in LRP5. J Bone Miner Res. 2015;30:615–620.
   Web of Science ®Google Scholar
• Weil YA, Rivkin G, Safran O, et al. The outcome of surgically treated femur fractures associated with long-term bisphosphonate use. J Trauma. 2011;71:186–190.
   Google Scholar
• Teo BJ, Koh JS, Goh SK, et al. Post-operative outcomes of atypical femoral subtrochanteric fracture in patients on bisphosphonate therapy. Bone Joint J. 2014;96-B:658–664.
   PubMed Web of Science ®Google Scholar
• Prasarn ML, Ahn J, Helfet DL, et al. Bisphosphonate-associated femur fractures have high complication rates with operative fixation. Clin Orthop Relat Res. 2012;470:2295–2301.
   PubMed Web of Science ®Google Scholar
• Verity DH, Wallace GR, Vaughan RW, et al. Behçet’s disease: from Hippocrates to the third millennium. Br J Ophthalmol. 2003;87:1175–1183.
   PubMed Web of Science ®Google Scholar
• International Study Group for Behçet’s Disease. Criteria for diagnosis of Behçet’s disease. Lancet. 1990;335:1078–1080.
   PubMed Web of Science ®Google Scholar
• Kirnap M, Calis M, Kaya N, et al. Is the Behcet’s disease a risk factor for osteoporosis and is relation to cytokines? Bratisl Lek Listy. 2010;111:340–344.
   Web of Science ®Google Scholar
• Hegde V, Jo JE, Andreopoulou P, et al. Effect of osteoporosis medications on fracture healing. Osteoporos Int. 2016;27:861–871.
   PubMed Web of Science ®Google Scholar
• Kamimura M, Nakamura Y, Ikegami S, et al. Bisphosphonate pre-treatment diminishes the therapeutic benefits of teriparatide in Japanese osteoporotic patients. Tohoku J Exp Med. 2016;239:17–24.
   Web of Science ®Google Scholar
• Nakamura Y, Suzuki T, Kamimura M, et al. Two-year clinical outcome of denosumab treatment alone and in combination with teriparatide in Japanese treatment-naive postmenopausal osteoporotic women. Bone Res. 2016;4:16055.
   Google Scholar
• Sato M, Grasser W, Endo N, et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 1991;88:2095–2105.
   PubMed Web of Science ®Google Scholar
• Lee KJ, Yoo JJ, Oh KJ, et al. Surgical outcome of intramedullary nailing in patients with complete atypical femoral fracture: a multicenter retrospective study. Injury. 2017;48:941–945.
   Web of Science ®Google Scholar
• Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25:2267–2294.
   PubMed Web of Science ®Google Scholar
• Moen MD, Keam SJ. Denosumab: a review of its use in the treatment of postmenopausal osteoporosis. Drugs Aging. 2011;28:63–82.
   Web of Science ®Google Scholar
• Adami S, Libanati C, Boonen S, et al. Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial. J Bone Joint Surg Am. 2012;94:2113–2119.
   PubMed Web of Science ®Google Scholar
• Bone HG, Wagman RB, Brandi ML, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5:513–523.
   PubMed Web of Science ®Google Scholar
• Goldhahn J, Féron JM, Kanis J, et al. Implications for fracture healing of current and new osteoporosis treatments: an ESCEO consensus paper. Calcif Tissue Int. 2012;90:343–353.
   PubMed Web of Science ®Google Scholar
• Im GI, Lee SH. Effect of teriparatide on healing of atypical femoral fractures: a systemic review. J Bone Metab. 2015;22:183–189.
   PubMedGoogle Scholar
• Vannucci L, Brandi ML. Healing of the bone with anti-fracture drugs. Expert Opin Pharmacother. 2016;17:2267–2272.
   PubMed Web of Science ®Google Scholar
• Hoes JN, Bultink IE, Lems WF. Management of osteoporosis in rheumatoid arthritis patients. Expert Opin Pharmacother. 2015;16:559–571.
   PubMed Web of Science ®Google Scholar